This content is machine translated Immunotherapy Subcutaneously or intravenously? New data on the efficacy of subcutaneous immunotherapies versus intravenous therapies in NSCLC underline not only the benefits for patients but also for healthcare professionals. This is shown by analyses...…
View Post 4 min This content is machine translated HER2-positive breast cancer and lymphoma New applications and antibodies The antibody-drug conjugate trastuzumab emtansine, T-DM1 (Kadcyla®), is composed of the antibody trastuzumab and the chemotherapeutic agent DM1 and is currently being investigated for the treatment of HER2-positive cancers. It…
